Amyris, Inc. (Emeryville, Calif.), a vertically integrated biomanufacturing company, announced that it will acquire Oobli Inc. (Davis, Calif.), a sweet protein innovator whose fermentation-based ingredients are used by food and beverage brands to reduce sugar without sacrificing taste.
According to the announcement, the transaction brings Amyris' scientific capabilities and manufacturing depth together with Oobli's protein fermentation expertise. It follows Amyris' expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and is described as a strategic commercial and technology expansion intended to accelerate the company's footprint in protein- and peptide-based solutions across end markets.
Sweet proteins and the Oobli portfolio
Oobli's commercial portfolio of sweet proteins would be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries found near the equator. Per the announcement, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.
The portfolio includes three products, each named for its source fruit and its corresponding protein:
- Oubli Fruit sweet protein, known scientifically as brazzein
- Serendipity Berry sweet protein, known scientifically as monellin
- Katemfe Fruit sweet protein, known scientifically as thaumatin
The company states that the portfolio holds FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor. With growing consumer awareness of metabolic health and the benefits of sugar reduction, sweet proteins are presented as a tool for brands across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.
How the companies frame the fit
Amyris Chief Executive Officer Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris' own, and that Oobli is poised to change how sweetness reaches the market. She added that combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden the company's reach in food and beverage, personal care, flavor and fragrances, agriculture and beyond.
Oobli Chief Executive Officer Ali Wing said the company has long held that there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. In her view, joining Amyris provides the scale and resources to pursue the ambition of making sweet proteins a global standard in sweetness solutions.
Fortmann also said that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform is intended to deliver sweet taste, sugar reduction and clean label at the same time. She welcomed the Oobli team into Amyris.
Timing and continuity
The acquisition is expected to close in the coming weeks. Amyris said that as the Oobli portfolio continues to expand within the company, all existing customer commitments and brand partnerships will be honored without interruption.
